Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients (original) (raw)
Alvarez RH, Kantarjian HM, Cortes JE . (2006). The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer107: 1918–1929. ArticleCAS Google Scholar
Bruno O, Brullo C, Bondavalli F, Ranise A, Schenone S, Tognolini M et al. (2007). 2-Amino/azido/hydrazino-5-alkoxy-5H-[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological evaluation. Med Chem3: 127–134. ArticleCAS Google Scholar
Chu S, Holtz M, Gupta M, Bhatia R . (2004). BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood103: 3167–3174. ArticleCAS Google Scholar
Dai Y, Rahmani M, Corey SJ, Dent P, Grant S . (2004). A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem279: 34227–34239. ArticleCAS Google Scholar
Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. (2003). BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood101: 690–698. ArticleCAS Google Scholar
Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB et al. (2004). Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res22: 5766–5774. Google Scholar
Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D et al. (2004). Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet36: 453–461. ArticleCASPubMed Central Google Scholar
Ilaria RL Jr, Hawley RG, Van Etten RA . (1999). Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood93: 4154–4166. CASPubMed Central Google Scholar
Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S et al. (2003). Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood101: 97–100. ArticleCAS Google Scholar
Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE et al. (2002). The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J21: 5766–5774. ArticleCASPubMed Central Google Scholar
Li L, Ren CH, Tahir SA, Ren C, Thompson TC . (2003). Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol23: 9389–9404. ArticleCASPubMed Central Google Scholar
Li M, Makkinje A, Damuni Z . (1996). The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem271: 11059–11062. ArticleCAS Google Scholar
Nawa M, Kanekura K, Hashimoto Y, Aiso S, Matsuoka M . (2008). A novel Akt/PKB-interacting protein promotes cell adhesion and inhibits familial amyotrophic lateral sclerosis-linked mutant SOD1-induced neuronal death via inhibition of PP2A-mediated dephosphorylation of Akt/PKB. Cell Signal20: 493–505. ArticleCASPubMed Central Google Scholar
Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. (2005). The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell8: 355–368. ArticleCAS Google Scholar
Nimmanapalli R, O’Bryan E, Huang M, Bali P, Burnette PK, Loughran T et al. (2002). Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res62: 5761–5769. CASPubMed Google Scholar
Pardanani A . (2008). AK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia22: 23–30. ArticleCAS Google Scholar
Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. (2007). TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia21: 1658–1668. ArticleCAS Google Scholar
Pathak MK, Yi T . (2001). Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol167: 3391–3397. ArticleCAS Google Scholar
Perrotti D, Neviani P . (2006). ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer95: 775–781. ArticleCASPubMed Central Google Scholar
Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM . (2004). Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med10: 1187–1189. ArticleCAS Google Scholar
Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG et al. (1994). Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J13: 764–773. ArticleCASPubMed Central Google Scholar
Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB . (2006). Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res66: 6468–6472. ArticleCAS Google Scholar
Sandberg EM, Ma X, He K, Frank SJ, Ostrov DA, Sayeski PP . (2005). Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem48: 2526–2533. ArticleCAS Google Scholar
Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. (2002). Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell1: 479–492. ArticleCAS Google Scholar
Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell7: 129–141. ArticleCAS Google Scholar
Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB . (1996). P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res56: 3426–3430. CAS Google Scholar
Wong S, Witte ON . (2004). The BCR-ABL story: bench to bedside and back. Annu Rev Immunol22: 247–306. ArticleCAS Google Scholar
Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z et al. (2008). Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib resistant chronic myelogenous leukemia cells. Blood7: 3821–3829. Article Google Scholar
Xie S, Lin H, Sun T, Arlinghaus RB . (2002). Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene21: 7137–7146. ArticleCAS Google Scholar
Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE et al. (2001). Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene20: 6188–6195. ArticleCAS Google Scholar
Yi T, Pathak MK, Lindner DJ, Ketterer ME, Farver C, Borden EC . (2002). Anticancer activity of sodium stibogluconate in synergy with IFNs. J Immunol169: 5978–5985. ArticleCAS Google Scholar
Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K et al. (2007). INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood109: 306–314. ArticleCAS Google Scholar
Yokoyama N, Reich NC, Miller WT . (2001). Involvement of protein phosphatase 2A in the interleukin-3-stimulated Jak2-Stat5 signaling pathway. J Interferon Cytokine Res21: 369–378. ArticleCAS Google Scholar
Yokoyama N, Reich NC, Miller WT . (2003). Determinants for the interaction between Janus kinase 2 and protein phosphatase 2A. Arch Biochem Biophys417: 87–95. ArticleCAS Google Scholar